
Danish pharmaceutical companies Novo Nordisk and Ascendis have renewed competition to look forward to in the market for treating dwarfism.
Pfizer announces in a press release that the US Food and Drug Administration has accepted for filing the initial Biologics License Application BLA for somatrogon, which, much like Novo Nordisk's Sogroya (somapacitan) and Ascendis' Transcon hGH is a weekly treatment for growth hormone deficiency.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app